Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Novo Nordisk and Septerna will jointly carry out research on the candidates from discovery to development candidate selection, with the Danish pharma group taking over responsibility as they ...

Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, T2D and other cardiometabolic diseases.

Novo also recently partnered with another biotech start-up, Septerna, to develop small molecules for weight loss and metabolic disorders. That collaboration is worth up to $2.2 billion between up ...

Novo Nordisk Is Europe’s Most Valuable Company—Again. Eli Lilly, Watch Out.© AFP via Getty Images The last time Novo Nordisk was Europe’s most valuable company was on March 24, 2025.

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...